ESR 12: Valentina Lucchini
Identification of novel cell wall biogenesis inhibitors
Valentina’s tasks encompass a mix of experimental work and desk research. All efforts are tightly linked to the success of the BioVersys team. Her main research focus lies on antibiotic resistance and virulence, as well as clinical microbiology. During her project at BioVersys Valentina will investigate a novel target involved in cell envelope homeostasis and integrate it into BioVersys’ technology platform. The resulting assays may enable primary screens of small molecule and/or natural product libraries to identify early Hit molecules. This work will be followed by Hit validation in alternative, secondary assays thus contributing to the biological work during the Hit-to-Lead optimization of identified compounds. Ultimately, a series of phenotypical assays will be developed to investigate the effect of identified molecules to the cell envelope biogenesis.
BioVersys AG, Switzerland
University of Basel, Biozentrum, Switzerland
Dr. Michel Pieren (BioVersys)
Prof. Dirk Bumann (UNIBAS)
Valentina Lucchini was born in Legnago, a small village near Verona in the north of Italy, in 1990. Her scientific education started by studying Biotechnology at the University of Verona, where she obtained her Bachelor degree in October 2012. After joining the University of Trento, Valentina continued her academic education in an English Master Program in Cellular and Molecular Biotechnology. Her scientific interest in Microbiology and Drug Development guided Valentina in 2014 to the BioVersys AG, an innovative Biotech company in Switzerland, where she performed her Master Thesis with a focus on assay development for DNA-protein interactions to validate novel drug targets able to switch-off drug resistance mechanisms in pathogenic bacteria. Valentina Lucchini finally obtained her Scientific Master degree with distinction in December 2014. From Mid-2015, she worked as a research associate at OncoXX Biotech Srl, a biotech company located in Chieti, Italy. Her research project focused on the production of humanized monoclonal antibodies involved in TROP2 signaling as potential novel anticancer therapeutic approach.
In February 2017, Valentina joined the Train2Target project as PhD student within a joint program of BioVersys AG, Switzerland, and the University of Basel.
Drug discovery created Valentina